Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome

Abstract

BackgroundHematologic disorders, including myelodysplastic syndrome (MDS), are difficult to identify in routine hematologic examinations using automated hematology analyzers. However, the practical uses of mean platelet component and mean platelet volume (MPV) measured by these analyzers as screening markers for MDS, remain unclear.MethodsMean platelet component and MPV values were measured in the peripheral blood of patients with MDS, aplastic anemia, idiopathic thrombocytopenic purpura, myeloproliferative neoplasms, and in healthy controls using an automated hematologic analyzer. Cutoff values for discriminating between the MDS group and healthy controls were determined by recursive partitioning analysis.ResultsMean platelet component was significantly lower in MDS patients compared with controls, while MPV was significantly higher. Combined cutoff values for MDS diagnosis of <25.3 g/dL for mean platelet component and >10.0 fL for MPV showed a specificity and positive predictive value of 99.9% and 99.1%, respectively. These cutoff values also differentiated between MDS and diagnoses of aplastic anemia, idiopathic thrombocytopenic purpura, and myeloproliferative neoplasms.ConclusionMean platelet component and MPV may, thus, be useful and convenient screening markers for MDS.

The effects of mean platelet volume and red cell distribution width on prognosis in patients with myelodysplastic syndrome

“…This gives us a clue for monitoring patients who show an increase in MPV values more closely during their follow-ups and perhaps preparing them for early stem cell transplantation. The percentage increase through time in the MPV values of the patients regardless of treatment was 2.3% in those who survived and 7.2% in those who died, while the difference between the two groups was not statistically significant [8]. Baba et al, associated RDW with clinical outcomes in MDS patients, and no significant correlation was found between RDW and prognosis in patients with increased blast counts, while a significant relationship was found between increased RDW (≥15.0%) and poor prognosis (p=0.0086) in MDS patients with refractory anemia [10].…”

“…A significant difference was observed among the hematological response rates of the groups that were assigned based on their IPSS values (p=0.021), and response rates decreased significantly as risk levels increased. Similarly, In the samples collected from 1304 healthy individuals, the mean MPV was 8.1±1.5 fL, while the mean MPV value was 8.9±2.9 fL in patients with aplastic anemia, 9.7±4.4 fL in ITP patients, and 9.0±2.7 fL in patients with myeloproliferative neoplasms, whereas it was relatively high at 12.0±5.0 fL in MDS patients (p<0.001) [8]. In our study, the MPV values of the patients who showed hematological response did not significantly change through the measurement times (p=0.077).…”

“…As evidenced by many different studies, an increase in the RDW value (typically over 14.6%) is recognized as a significant marker for morbidity and mortality in the general population [6,7]. In some studies, an increase in MPV values was found between the control group and the group with MDS, but no relationship was established with mortality [8]. According to the recent studies investigated the relationship between MPV to platelet ratio and survival in MDS patients, and this index was found to be higher in patients over 70 years of age, and a positive correlation was observed with the IPSS scores [9].…”

Sclerostin Depletion Induces Inflammation in the Bone Marrow of Mice

“…We know that Sost −/− mice have normal hemoglobin levels (Table S2), indicating no issues with iron; however, iron levels in Sost −/− mice have not been directly quantified to date. The increase in mean platelet volume (MPV) in the blood is usually associated with an increase in platelet production, or destruction of platelets, as seen in myeloproliferative diseases [84][85][86], such as chronic myeloid leukemia (CML), myelofibrosis, and myelodysplastic syndrome (MDS) [87][88][89]. Sost −/− mice displayed no changes in the blood platelet levels (Table S2).…”

Sclerostin depletion induces inflammation in the bone marrow of mice

“…We know that Sost -/mice have normal hemoglobin levels (Supplemental Table 2) indicating no issues with iron; however, iron levels in Sost -/mice have not been directly quantified to date. The increase in mean platelet volume (MPV) in the blood is usually associated with an increase in platelet production, or destruction of platelets as seen in myeloproliferative diseases (64)(65)(66) such as chronic myeloid leukemia (CML), myelofibrosis, and myelodysplastic syndrome (MDS) (67)(68)(69). Sost -/mice displayed no changes in the blood platelet levels (data not shown).…”